Vasopharm BIOTECH GmbH & Co. KG

Vasopharm BIOTECH develops innovative drugs and diagnostics that treat one of the major pathomechanisms of CVD, i.e. endothelial dysfunction. It is generally accepted that one underlying mechanism of CVD is a dysfunctional inner layer of the blood vessel, the so- called endothelium. Endothelial dysfunction can be observed in patients suffering from different CVD such as arterial hypertension, elevated plasma cholesterol and/or triglyceride levels, angina pectoris, transitorial ischemic attacks, atherosclerosis and even diabetes mellitus. A dysfunctional endothelium occurs long before cardiovascular complications become apparent. Thus measurement of endothelial function is of great importance in order to identify risk patients and patients that will benefit from vasopharm BIOTECH's drugs.Vasopharm BIOTECH will develop drugs up to the stage proof of principle in man, normally clinical phase II. Importantly, the core competence of vasopharm BIOTECH is concentrated in CVD. However, vasopharm BIOTECH's development projects are likely to generate also drug candidates for other therapeutic areas along the NO/cGMP pathway, e.g. inflammation, sepsis, asthma etc. For these non-cardiovascular indications, vasopharm BIOTECH is seeking collaborations at late preclinical or early clinical stages with pharmaceutical companies specialized in these non-cardiovascular areas.

Activity:

- Research & Development

Product / Technology type(s) covered:

- Diagnostics
- Pharmaceuticals / Therapeutics

Therapeutic targets:

Markets Covered

a. HeadQuarter:

b. Continent(s) active: Europe , North America

c. Countries active:

Corporate data:

Number of Employees:

Turnover:

Amount:	Year:	Currency:

Year founded: